Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Immunovaccine begins trading as “IMV”

Immunovaccine Inc. (TSX-V:IMV) will begin trading on the TSX-Venture Exchange as a Tier 1 issuer under the ticker symbol “IMV”. Immunovaccine Inc. also announces the closing of the previously announced private placement totaling $8,269,109 in gross proceeds. The TSX Venture Exchange has accepted the private placement for filing.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data, that depending Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. The Phase I study will evaluate safety, tolerability and the immune response of the Company’s H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of the study are expected during the fourth quarter of 2009. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Provectus starts Phase 1 trial for liver cancer treatment

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver cancer that will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma. The primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta (IL-1 beta), XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseases. The clinical trials are designed to further evaluate the use of multiple dose regimens on the safety, pharmacodynamics and efficacy of XOMA 052 in cardiometabolic and other diseases, and based on positive results, select doses for pivotal Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,